Scholar Rock (SRRK) Expected to Announce Earnings on Tuesday

Scholar Rock (NASDAQ:SRRK - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Tuesday, May 6th. Analysts expect Scholar Rock to post earnings of ($0.63) per share for the quarter.

Scholar Rock Price Performance

Shares of SRRK opened at $31.67 on Tuesday. The company has a market capitalization of $3.00 billion, a P/E ratio of -13.48 and a beta of 0.56. Scholar Rock has a twelve month low of $6.76 and a twelve month high of $46.98. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.63. The firm has a 50 day moving average of $32.64 and a 200 day moving average of $35.76.

Wall Street Analysts Forecast Growth

Separately, Wedbush reaffirmed an "outperform" rating and issued a $50.00 price objective on shares of Scholar Rock in a research report on Tuesday, March 25th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $42.67.

Insider Activity at Scholar Rock

In other Scholar Rock news, insider Mo Qatanani sold 68,510 shares of the business's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $37.40, for a total transaction of $2,562,274.00. Following the transaction, the insider now owns 111,084 shares in the company, valued at $4,154,541.60. The trade was a 38.15 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Katie Peng sold 1,006 shares of the firm's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $34.42, for a total value of $34,626.52. Following the sale, the director now owns 30,319 shares of the company's stock, valued at $1,043,579.98. This represents a 3.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 250,231 shares of company stock worth $9,056,086 over the last 90 days. Company insiders own 13.30% of the company's stock.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.